Latest news
AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday's ABCL635 Phase 2 Trial Results - TechStock²TechStock² · Sat, 08 Aug 2026 14:45:00 GMTAbCellera Biologics | 8-K: Current report - MoomooMoomoo · Sat, 08 Aug 2026 02:26:46 GMTABCL Looks 34.6% Overvalued on GF Value™ - GuruFocusGuruFocus · Sat, 08 Aug 2026 00:47:13 GMTStocks to Watch: AbCellera - MoomooMoomoo · Fri, 07 Aug 2026 23:36:50 GMT12 Health Care Stocks Moving In Friday's After-Market Session - BenzingaBenzinga · Fri, 07 Aug 2026 21:05:58 GMTAbCellera to Release Phase 2 Top-Line Results for ABCL635 and Host Investor Call Aug 10 - TradingViewTradingView · Fri, 07 Aug 2026 20:53:02 GMTAbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 - Business WireBusiness Wire · Fri, 07 Aug 2026 20:30:00 GMTABCL Maintained by Stifel -- Price Target Raised to $9.00 - GuruFocusGuruFocus · Thu, 06 Aug 2026 16:08:38 GMT